IL-35 inhibits CD8+ T cells activity by suppressing expression of costimulatory molecule CD28 and Th1 cytokine production.

Abstract

BACKGROUND:

Interleukin-35 (IL-35), a novel immune-suppressing cytokine, can promote tumor angiogenesis and inhibits anti-tumor cytotoxic lymphocyte response. Here, we aimed to investigate the potential mechanism of the effects of IL-35 on anti-tumor cytotoxic lymphocyte.

METHODS:

Dendritic cells (DCs) were used to induce anti-tumor cytotoxic lymphocyte. Flow cytometry, carboxyfluorescein succinimidyl ester staining, ELISA assay and western blotting were used to analyze the effect of IL-35 on anti-tumor cytotoxic lymphocyte.

RESULTS:

We observed that IL-35 inhibited the expression of costimulatory molecule CD28 on CD8+ T cell surface and Th1 cytokine production. However, IL-35 did not inhibit anti-tumor cytotoxic lymphocyte proliferation nor enhance the expression of apoptosis-related proteins of anti-tumor cytotoxic lymphocyte. Moreover, IL-35 did not repress the expression of Fas ligand (FasL) on cytotoxic lymphocyte surface.

CONCLUSIONS:

Our findings revealed that IL-35 can inhibit CD8+ T cells activity by suppressing the expression of costimulatory molecule CD28 and Th1 cytokine production.

• Authors: Hua Jiang, Ting Zhang, Mao-Xiao Yan, Wei Wu
• Journal: Translational cancer research (Transl Cancer Res) Vol. 8 Issue 4 Pg. 1319-1325 (Aug 2019) ISSN: 2219-6803 [Electronic] China
• PMID: 35116874 (Publication Type: Journal Article)
• Copyright: 2019 Translational Cancer Research. All rights reserved.